Titlebook: New Data and Updates for I-VII, III-V and II-VI Compounds; Volume 44, Subvolume U. R?ssler Book 20111st edition Springer-Verlag Berlin Heid

交叉路口

書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds影響因子(影響力)




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds被引頻次




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds被引頻次學(xué)科排名




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds年度引用




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds年度引用學(xué)科排名




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds讀者反饋




書(shū)目名稱(chēng)New Data and Updates for I-VII, III-V and II-VI Compounds讀者反饋學(xué)科排名

ORBIT

智力高

tients as therapeutic substances in itself already justifies at least some legal control. The human origin of these substances and their natural scarcity are further reasons for interference by society and the legislator.

Projection

tients as therapeutic substances in itself already justifies at least some legal control. The human origin of these substances and their natural scarcity are further reasons for interference by society and the legislator.

ascetic

t into what actually happens during disciplinary moments that ultimately leads to the disproportional tracking of particular students into exclusionary school disciplinary consequences, which funnels an undercl978-94-6209-449-9Series ISSN 2214-9864 Series E-ISSN 2214-9872

intrude

我要威脅

消極詞匯

擴(kuò)音器

a and hyperchloremia. Further research is warranted to determine the optimal agent and their best means of administration (boluses vs. continuous infusions) for each neurocritical condition. More extensive clinical trials are needed to address long-term outcomes, adverse events, and quality of life with both agents.

mediocrity

view on balanced intravenous solutions, firstly, by providing a physiological background of balanced solutions; secondly, by summarizing their potential pathophysiologic effects; and lastly, by presenting the clinical evidence available at the present time to support or refute their use in specific neurosurgical scenarios.